Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, has received an order from the Assistant Commissioner & Licensing Authority, Food & Drug Administration, Nagpur, suspending the drug license of one store at Vishwakarma Nagar, Nagpur for fifteen days. The action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940 and the associated Rules. The order was received on September 24, 2025. The company estimates a potential revenue loss of approximately Rs 2.29 lakhs due to this suspension. The matter has been disclosed under SEBI Listing Regulations for transparency.
The financial impact is minimal at around Rs 2.29 lakhs for a single store, and is unlikely to materially affect the company's overall operations or stock price. It is a routine regulatory compliance issue at one retail outlet among many.